In this randomized , double-blind study , 27 Japanese treatment-naive patients received once-daily daclatasvir 10 mg or 60 mg or placebo , each combined with peginterferon alfa-2b / ribavirin ; 18 prior null ( n = 9 ) or partial ( n = 9 ) responders received the same daclatasvir-containing regimens without a placebo arm .